Neoplasms by Histologic Type  >>  Torisel (temsirolimus)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

22 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Torisel (temsirolimus) / Pfizer
NCT00086840: CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Terminated
2
60
US
temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel, laboratory biomarker analysis
National Cancer Institute (NCI)
Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia
08/05
 
NCT00087074: CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor

Completed
2
55
US
temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel, laboratory biomarker analysis
National Cancer Institute (NCI)
Gastrointestinal Stromal Tumor, Recurrent Adult Soft Tissue Sarcoma, Stage I Adult Soft Tissue Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
12/05
 
NCT00800917 / 2008-003679-40: A Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme

Completed
2
12
Europe
Temsirolimus, Bevacizumab
Rigshospitalet, Denmark, University of Copenhagen, Wyeth is now a wholly owned subsidiary of Pfizer, Roche, Copenhagen
Glioblastoma Multiforme
02/10
02/10
NCT00290472: CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Completed
2
89
US
temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel
National Cancer Institute (NCI)
B-cell Chronic Lymphocytic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Malignant Neoplasm, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
04/10
04/10
OCR, NCT00743509: A Phase II Study of Oral Cyclophosphamide and Sirolimus () in Advanced Sarcoma

Checkmark Data-ASCO
Jun 2011 - Jun 2011: Data-ASCO
Completed
2
49
US
Cyclophosphamide and Sirolimus, Sirolimus (rapamycin, Rapamune)
University of Michigan Rogel Cancer Center
Osteosarcoma
04/10
09/12
NCT00494091: Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma

Checkmark P2 data
Jul 2012 - Jul 2012: P2 data
Completed
2
82
Japan, RoW
Temsirolimus (CCI-779), Torisel
Pfizer
Advanced Renal Cell Carcinoma
05/11
03/12
TEMHEAD, NCT01172769: Efficacy Study of Temsirolimus to Treat Head and Neck Cancer

Checkmark ECCO-ESMO-ESTRO 2013
Sep 2013 - Sep 2013: ECCO-ESMO-ESTRO 2013
Checkmark P2 data - ESMO 2012
Sep 2012 - Sep 2012: P2 data - ESMO 2012
Completed
2
42
Europe
Temsirolimus, Torisel, mTOR inhibitor, protein kinase inhibitor
Hannover Medical School
Head and Neck Squamous Cell Carcinoma
03/12
03/12
NCT00775593 / 2007-005374-31: Clofarabine and Temsirolimus in Treating Older Patients With Relapsed or Refractory Acute Myeloid Leukemia

Checkmark P2 data
Nov 2011 - Nov 2011: P2 data
Completed
2
60
Europe
clofarabine, temsirolimus
Gruppo Italiano Malattie EMatologiche dell'Adulto
Leukemia
06/12
10/13
NCT01166126: Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV

Terminated
2
4
US
temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel, selumetinib, ARRY-142886, AZD6244, laboratory biomarker analysis
National Cancer Institute (NCI)
Mucosal Melanoma, Recurrent Melanoma, Stage IV Melanoma
06/12
06/12
NCT01234974: IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus

Withdrawn
2
0
US
Pasireotide, Pasireotide s.c., Pasireotide LAR, SOM230, Everolimus, RAD001
Milton S. Hershey Medical Center
Multiple Myeloma
12/12
12/13
MAESTRO HN, NCT01256385: Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
2
86
US, RoW
Cetuximab, Chimeric Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225, Chimeric Monoclonal Antibody C225, Erbitux, IMC-C225, Laboratory Biomarker Analysis, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel
National Cancer Institute (NCI)
Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Recurrent Oral Cavity Verrucous Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Salivary Gland Carcinoma, Salivary Gland Squamous Cell Carcinoma, Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary, Stage IV Hypopharyngeal Squamous Cell Carcinoma, Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Stage IVA Laryngeal Squamous Cell Carcinoma, Stage IVA Laryngeal Verrucous Carcinoma, Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVA Major Salivary Gland Carcinoma, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVA Oral Cavity Verrucous Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Laryngeal Squamous Cell Carcinoma, Stage IVB Laryngeal Verrucous Carcinoma, Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVB Major Salivary Gland Carcinoma, Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVB Oral Cavity Verrucous Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Laryngeal Squamous Cell Carcinoma, Stage IVC Laryngeal Verrucous Carcinoma, Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVC Major Salivary Gland Carcinoma, Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVC Oral Cavity Verrucous Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma, Tongue Carcinoma
12/13
12/13
NCT01016015: Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma

Checkmark +temsirolimus
Mar 2013 - Mar 2013: +temsirolimus
Checkmark P2 data - ASCO
Jun 2012 - Jun 2012: P2 data - ASCO
Checkmark P2 data
More
Completed
2
178
US, Canada
Cixutumumab, Anti-IGF-1R Recombinant Monoclonal Antibody IMC-A12, IMC-A12, Laboratory Biomarker Analysis, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel
National Cancer Institute (NCI)
Metastatic Osteosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Osteosarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
07/14
07/14
NCT01206140: Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
2
70
US
Laboratory Biomarker Analysis, Selumetinib, ARRY-142886, AZD6244, MEK Inhibitor AZD6244, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel
National Cancer Institute (NCI), National Comprehensive Cancer Network
Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
04/15
04/15
NCT00923845: Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer

Completed
2
25
US
Pentostatin, Nipent, Sirolimus, Rapamune, Cyclophosphamide, Cytoxan, Allogeneic Hematopoietic Stem Cell Transplant (HSCT), Th2 rapa cells, Donor Lymphocyte Harvest, Induction Therapy, GVHD prophylaxis, Donor Hematopoietic Stem Cell Harvest
National Cancer Institute (NCI)
Renal Cell Carcinoma, Graft-Versus-Host Disease, Engraftment Syndrome
06/15
06/17
NCT01222715: Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
2
87
US, Canada, RoW
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Laboratory Biomarker Analysis, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel, Vinorelbine Tartrate, Biovelbin, Eunades, KW-2307, Navelbine, Navelbine Ditartrate, NVB, Vinorelbine Ditartrate
National Cancer Institute (NCI)
Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Pleomorphic Rhabdomyosarcoma, Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Rhabdomyosarcoma
06/15
06/15
NCT01010126: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Checkmark P2 data-ASCO
Jun 2012 - Jun 2012: P2 data-ASCO
Checkmark P2 data
More
Completed
2
252
Canada, US
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar FKB238, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel
National Cancer Institute (NCI)
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Endometrial Serous Adenocarcinoma, Localized Non-Resectable Adult Liver Carcinoma, Lung Carcinoid Tumor, Malignant Pancreatic Gastrinoma, Malignant Pancreatic Glucagonoma, Malignant Pancreatic Insulinoma, Malignant Pancreatic Somatostatinoma, Metastatic Digestive System Neuroendocrine Tumor G1, Ovarian Carcinosarcoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Surface Papillary Adenocarcinoma, Pancreatic Alpha Cell Adenoma, Pancreatic Beta Cell Adenoma, Pancreatic Delta Cell Adenoma, Pancreatic G-Cell Adenoma, Pancreatic Polypeptide Tumor, Recurrent Adult Liver Carcinoma, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Neuroendocrine Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Regional Digestive System Neuroendocrine Tumor G1, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIA Uterine Corpus Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIB Uterine Corpus Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IIIC Uterine Corpus Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Stage IVA Uterine Corpus Cancer, Stage IVB Uterine Corpus Cancer, Uterine Carcinosarcoma
03/17
03/17
NCT00417677: A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma

Terminated
1/2
124
US
Combination of Temsirolimus and Sunitinib
Wyeth is now a wholly owned subsidiary of Pfizer
Renal Cell Carcinoma
 
05/07
NCT00787969: Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Checkmark For initial therapy of mantle cell lymphoma
Jul 2014 - Jul 2014: For initial therapy of mantle cell lymphoma
Completed
1/2
74
US
rituximab, cladribine, temsirolimus, Filgrastim, Pegfilgrastim
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Lymphoma
04/12
06/17
NCT01170052 / 2009-014844-13: Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)

Withdrawn
1/2
20
Europe
Temsirolimus, Torisel®, Bendamustine
Charite University, Berlin, Germany, Wyeth is now a wholly owned subsidiary of Pfizer, Mundipharma K.K.
Mantle Cell Lymphoma
04/12
04/14
NCT00949325: Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark Temsirolimus+Liposomal doxorubicin
Feb 2013 - Feb 2013: Temsirolimus+Liposomal doxorubicin
Completed
1/2
24
US
temsirolimus plus liposomal doxorubicin, Torisel, Doxil
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Comprehensive Cancer Network, Wyeth is now a wholly owned subsidiary of Pfizer
Sarcoma
09/12
09/12
NCT01335074: Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

Withdrawn
1/2
0
Europe
Temsirolimus + Sorafenib
Philipps University Marburg Medical Center
Hepatocellular Carcinoma
12/13
 
BERT, NCT01078142 / 2009-013351-30: Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma

Checkmark ICML 2013
Jun 2013 - Jun 2013: ICML 2013
Checkmark Interim P1/2 data in FL, MCL
Nov 2011 - Nov 2011: Interim P1/2 data in FL, MCL
Completed
1/2
39
Europe
Temsirolimus, Rituximab, Bendamustin, Mabthera, Rituxan, Torisel, Bendamustin, Ribomustin, Trenda
Georg Hess, MD, Wyeth is now a wholly owned subsidiary of Pfizer, Mundipharma Pte Ltd.
Follicular Lymphoma, Mantle Cell Lymphoma
09/17
09/17

Download Options